Allscripts (NASDAQ: MDRX) reported Q2 EPS of $0.18, in-line with the analyst estimate of $0.18. Revenue for the quarter came in at $536 million versus the consensus estimate of $538.16 million.

GUIDANCE:

Allscripts sees FY2018 EPS of $0.72-$0.82 vs $0.77. Allscripts sees FY2018 revenue of $2.15-2.25 million, versus the consensus of $2.18 million.

Stock Repurchase

Stock repurchases totaled $44 million in the second quarter of 2018, for a year-to-date stock repurchase total of $102 million.

Allscripts announces today that its Board of Directors approved a new stock repurchase program under which Allscripts may purchase up to $250 million of its common stock through 2020. The new stock repurchase program replaces the previously existing program.

Allscripts plans to repurchase shares from time to time in the open market or in privately negotiated transactions, subject to market conditions. There is no guarantee as to the exact number of shares or value that will be repurchased under the stock repurchase program, and Allscripts may discontinue purchases at any time. Whether Allscripts makes any repurchases will depend on many factors, including but not limited to its business and financial performance, the business and market conditions at the time, including the price of Allscripts shares, and other factors that management considers relevant.

For earnings history and earnings-related data on Allscripts (MDRX) click here.